Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have b...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jakate A, McNamee B, Burkindine D
Format: article
Langue:EN
Publié: Dove Medical Press 2019
Sujets:
Delzicol
Asacol
mesalamine
inflammatory bowel disease
ulcerative colitis
Therapeutics. Pharmacology
RM1-950
Accès en ligne:https://doaj.org/article/02aecee68087414c8e7a96c3eed0a793
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/02aecee68087414c8e7a96c3eed0a793

Documents similaires